Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis

Chih-Wei Fu,Han-En Tsai,Wei-Sheng Chen,Tzu-Ting Chang,Chia-Ling Chen,Pei-Wen Hsiao,Wen-Shan Li
DOI: https://doi.org/10.1021/acs.jmedchem.0c01477
IF: 8.039
2020-12-28
Journal of Medicinal Chemistry
Abstract:We report the synthesis and evaluation of a series of cell-permeable and N- versus O-selective sialyltransferase inhibitors. Inhibitor design entailed the functionalization of lithocholic acid at C(3) and at the cyclopentane ring side chain. Among the series, FCW34 and FCW66 were shown to inhibit MDA-MB-231 cell migration as effectively as ST3GALIII-gene knockdown did. FCW34 was shown to inhibit tumor growth, reduce angiogenesis, and delay cancer cell metastasis in animal models. Furthermore, FCW34 inhibited vessel development and suppressed angiogenic activity in transgenic zebrafish models. Our results provide clear evidence that FCW34-induced sialyltransferase inhibition reduces cancer cell metastasis by decreasing N-glycan sialylation, thus altering the regulation of talin/integrin/FAK/paxillin and integrin/NFκB signaling pathways.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01477?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01477</a>.Effect of <b>2aA</b>–<b>2eA</b> on migration in MDA-MB-231 cells; effect of FCW34 on migration in MDA-MB-231 cells; effect of FCW66 on migration in MDA-MB-231 cells; effects of ST3GALIII siRNA knockdown efficiency in MDA-MB-231 cells; inhibition of integrin sialylation by sialyltransferase inhibitors in MDA-MB-231 cells; effects of sialyltransferase inhibitor FCW34 on tumor metastasis in MDA-MB-231 breast cancer cells in vivo; effects of sialyltransferase inhibitor FCW34 on toxicity assessment in MDA-MB-231 breast cancer cells in vivo; effects of sialyltransferase inhibitors on the integrin–FAK–paxillin pathway in MDA-MB-231 cells; effects of sialyltransferase inhibitors on the NFκB pathway in MDA-MB-231 cells; apparent permeability (<i>P</i><sub>app</sub>) values obtained for the reference compounds, FCW34, and FCW66 using the PAMPA model; endogenous expression of ST6GALI, ST3GALIII, ST3GALI, and ST6GALNACI proteins; comparison of binding modes of <b>2aA</b>–<b>2eA</b>, <b>3cB</b>–<b>3dB</b>, <b>4cC</b>–<b>4dC</b>, AL10, LCAG, and Lith-<i>O</i>-ASP in the binding sites of two asymmetric polypeptide chains (A/B) of ST6GALI (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QVT">6QVT</a>); computed physicochemical properties of the selected compounds used in this study; computational binding values of complex structure of ST6GALI-inhibitor; sensitization of tumors to ST inhibitors by regulation of the talin/integrin/FAK/paxillin and integrin/NFκB-signaling pathways; and experimental procedures, details of HPLC-determined purity data, HRMS results, and <sup>1</sup>H and <sup>13</sup>C NMR spectra of all final compounds and intermediates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01477/suppl_file/jm0c01477_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01477/suppl_file/jm0c01477_si_002.csv">CSV</a>)This article has not yet been cited by other publications.
chemistry, medicinal
What problem does this paper attempt to address?